PROTAC 工程化蛋白/DNA 纳米抗原是癌症免疫治疗中树突状细胞疫苗的有效增强剂
PROTAC-Engineered Protein/DNA Nanoantigen is a Potent Booster for Dendritic Cell Vaccines in Cancer Immunotherapy.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
抗肿瘤树突状细胞疫苗的最新进展
英文原题：Recent Advances in Antitumor Dendritic Cell Vaccines.
查看英文原题
Recent Advances in Antitumor Dendritic Cell Vaccines.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
背景
树突状细胞（DC）是体内最重要的抗原提呈细胞，在抗原识别、摄取、加工及提呈中发挥关键作用，并介导非特异性免疫和特异性免疫。
目的
总结DC疫苗是一种结合肿瘤抗原和DC优势的新型免疫治疗方案，能够增强机体对肿瘤的识别和清除能力的主要发现。
方法
在这篇综述中，作者聚焦于DC的生物学特征、抗肿瘤机制认识的最新进展以及DC疫苗的分类。
结果
系统总结了DC疫苗免疫治疗在中国高发病率或高死亡率常见肿瘤中的当前进展。
结论
结合肿瘤抗原优势的DC疫苗将为未来探索合理、安全、有效的肿瘤联合免疫治疗策略提供方向。
展开英文摘要原文
Background: Dendritic cells (DCs) are the most important antigen-presenting cells in the body and play a key role in antigen recognition, uptake, processing, and presentation and mediate nonspecific immunity and specific immunity. Purpose: To summarize the main findings that DC vaccines are a new immunotherapy scheme combining the strengths of tumor antigens and DCs that can boost the body's identification and clearance of tumors.
Methods: In this review, the authors focus on the biological characteristics of DCs, recent advances in the understanding of antitumor mechanisms, and the classification of DC vaccines. Results: The current progress of DC-based vaccine immunotherapy for common tumors with high morbidity or mortality in China were systematically summarize. Conclusions: The DC vaccines combining the strengths of tumor antigens will provide directions to explore reasonable, safe, and effective combination immunotherapy strategies for tumors in the future.
论文信息
- 作者
- Ge C、Yang X、Xin J、Gong X、Wang X、Kong L
- 第一作者单位
- Institute of Medical Artificial Intelligence, Binzhou Medical University, Yantai, China.China
- 通讯作者单位
- Department of Biochemistry and Molecular Biology, Binzhou Medical University, Yantai, China.China
- 文献类型
- 综述
- 期刊
- Cancer biotherapy & radiopharmaceuticals2023 Sep
- 原文标识
- PubMed 37699203 · DOI 10.1089/cbr.2023.0041